|  |
| --- |
| [Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11730). NICE technology appraisal guidance [ID6378]. Publication date to be confirmed |
| [Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer](https://www.nice.org.uk/guidance/indevelopment/gid-ta11199). NICE technology appraisal guidance [ID6215]. Publication date to be confirmed |
|  |
|  |
| [Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy](https://www.nice.org.uk/guidance/indevelopment/gid-ta11163). NICE technology appraisal guidance [ID6203]. Publication date to be confirmed |
| [Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer](https://www.nice.org.uk/guidance/indevelopment/gid-ta11557). NICE technology appraisal guidance [ID6452]. Publication expected September 2025 |
| [Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer](https://www.nice.org.uk/guidance/indevelopment/gid-ta11443). NICE technology appraisal guidance [ID6419]. Publication date to be confirmed |
| [Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer](https://www.nice.org.uk/guidance/indevelopment/gid-ta10779). NICE technology appraisal guidance [ID3889]. Publication date to be confirmed |
| [Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy](https://www.nice.org.uk/guidance/indevelopment/gid-ta10696). NICE technology appraisal guidance [ID3814]. Publication date to be confirmed |
| [SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)](https://www.nice.org.uk/guidance/indevelopment/gid-mt526). NICE medical technologies guidance. Publication date to be confirmed |
| [Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer](https://www.nice.org.uk/guidance/indevelopment/gid-ta10904). NICE technology appraisal guidance [ID4004]. Publication expected October 2025 |

## [1] TRUE